Reihe „Bürger*innenbeteiligung im Teilprojekt Vulnerabilität und Sicherheit in der gerechten Stadt (VERSS)“

Das vorliegende Working Paper ist das erste einer zweiteiligen Working‐Paper‐Reihe zum Thema „Bürger*innenbeteiligung“, die im Rahmen des vom BMBF geförderten Teilprojekts„Vulnerabilität und Sicherheit in der gerechten Stadt“ entstanden sind. Es bespricht die verschiedenen Verfahrensweisen in und Umgänge mit der Beteiligung von Bürger*innen. Zu diesem Zweck bereitet es den so genannten State of the Art auf und bespricht dabei den Aspekt der sozialen Nachhaltigkeit von Bürger*innenbeteiligung. Eine sozialnachhaltige Gestaltung und Planung von Beteiligungsverfahren zielt auf „passgenaue“ und sozialverträgliche Maßnahmen und Entwicklungen, die auf Kooperation, Anerkennung und Transparenz fußen. Welche Schritte gilt es dabei zu bedenken und wie werden Beteiligungsverfahren in der Forschung besprochen? Das vorliegende Working Paper stellt zunächst die Debatte zur Partizipation mit einem Anwendungsschwerpunkt auf Kommunen vor. Im Anschluss diskutieren wir eine Methodologie, die die theoretischen Argumente aufgreift und in die Anwendung durch den VERSS‐Werkzeugkasten mündet

Occurrence and distribution of Amphidomataceae (Dinophyceae) in Danish coastal waters of the North Sea, the Limfjord and the Kattegat/Belt area

Some species of the dinophytes Azadinium and Amphidoma (Amphidomataceae) produce azaspiracids (AZA), lipophilic polyether compounds responsible for Azaspiracid Shellfish Poisoning (AZP) in humans after consumption of contaminated seafood. Toxigenic Amphidomataceae are known to occur in the North Atlantic and the North Sea area, but little is known about their importance in Danish coastal waters. In 2016, 44 Stations were sampled on a survey along the Danish coastline, covering the German Bight, Limfjord, the Kattegat area, Great Belt and Kiel Bight. Samples were analysed by live microscopy, liquid chromatography-tandem mass spectrometry (LC–MS/MS) and quantitative polymerase-chain-reaction (qPCR) on the presence of Amphidomataceae and AZA. Amphidomataceae were widely distributed in the area, but were below detection limit on most of the inner Limfjord stations. Cell abundances of the three toxigenic species, determined with species-specific qPCR assays on Azadinium spinosum, Az. poporum and Amphidoma languida, were generally low and restricted to the North Sea and the northern Kattegat, which was in agreement with the distribution of the generally low AZA abundances in plankton samples. Among the toxigenic species, Amphidoma languida was dominant with highest cell densities up to 3×103 cells L−1 on North Sea stations and at the western entrance of the Limfjord. Azaspiracids detected in plankton samples include low levels of AZA-1 at one station of the North Sea, and higher levels of AZA-38 and -39 (up to 1.5 ng L−1) in the North Sea and the Limfjord entrance. Furthermore, one new AZA (named AZA-63) was discovered in plankton of two North Sea stations. Morphological, molecular, and toxinological characterisation of 26 newly established strains from the area confirmed the presence of four amphidomatacean species (Az. obesum, Az. dalianense, Az. poporum and Am. languida). The single new strain of Az. poporum turned out as a member of Ribotype A2, which was previously only known from the Mediterranean. Consistent with some of these Mediterranean A2 strains, but different to the previously established AZA-37 producing Az. poporum Ribotype A1 strains from Denmark, the new strain did not contain any AZA. Azaspiracids were also absent in all Az. obesum and Az. dalianense strains, but AZA-38 and -39 were found in all Am. languida strains with total AZA cell quotas ranging from 0.08 up to 94 fg cell−1. In conclusion, AZA-producing microalgae and their respective toxins were low in abundance but widely present in the area, and thus might be considered in local monitoring programs to preserve seafood safety in Danish coastal waters

An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission

The development of effective SARS-CoV-2 vaccines has been essential to control COVID-19, but significant challenges remain. One problem is intramuscular administration, which does not induce robust mucosal immune responses in the upper airways—the primary site of infection and virus shedding. Here we compare the efficacy of a mucosal, replication-competent yet fully attenuated virus vaccine, sCPD9-ΔFCS, and the monovalent mRNA vaccine BNT162b2 in preventing transmission of SARS-CoV-2 variants B.1 and Omicron BA.5 in two scenarios. Firstly, we assessed the protective efficacy of the vaccines by exposing vaccinated male Syrian hamsters to infected counterparts. Secondly, we evaluated transmission of the challenge virus from vaccinated and subsequently challenged male hamsters to naïve contacts. Our findings demonstrate that the live-attenuated vaccine (LAV) sCPD9-ΔFCS significantly outperformed the mRNA vaccine in preventing virus transmission in both scenarios. Our results provide evidence for the advantages of locally administered LAVs over intramuscularly administered mRNA vaccines in preventing infection and reducing virus transmission

ISS-Experiments of Columnar-to-Equiaxed Transition in Solidification Processing

The main topic of the research project CETSOL in the framework of the Microgravity Application Promotion (MAP) programme of the European Space Agency (ESA) is the investigation of the transition from columnar to equiaxed grain growth during solidification. Microgravity environment allows for suppression of buoyancy-driven melt flow and for growth of equiaxed grains free of sedimentation and buoyancy effects. This contribution will present first experimental results obtained in microgravity using hypo-eutectic AlSi alloys in the Materials Science Laboratory (MSL) on-board the International Space Station (ISS). The analysis of the experiments confirms the existence of a columnar to equiaxed transition, especially in the refined alloy. Temperature evolution and grain structure analysis provide critical values for the position, the temperature gradient and the solidification velocity at the columnar to equiaxed transition. These data will be used to improve modeling of solidification microstructures and grain structure on different lengths scales

European Radiometry Buoy and Infrastructure (EURYBIA): A Contribution to the Design of the European Copernicus Infrastructure for Ocean Colour System Vicarious Calibration

In the context of the Copernicus Program, EUMETSAT prioritizes the creation of an ocean color infrastructure for system vicarious calibration (OC-SVC). This work aims to reply to this need by proposing the European Radiometry Buoy and Infrastructure (EURYBIA). EURYBIA is designed as an autonomous European infrastructure operating within the Marine Optical Network (MarONet) established by University of Miami (Miami, FL, USA) based on the Marine Optical Buoy (MOBY) experience and NASA support. MarONet addresses SVC requirements in different sites, consistently and in a traceable way. The selected EURYBIA installation is close to the Lampedusa Island in the central Mediterranean Sea. This area is widely studied and hosts an Atmospheric and Oceanographic Observatory for long-term climate monitoring. The EURYBIA field segment comprises off-shore and on-shore infrastructures to manage the observation system and perform routine sensors calibrations. The ground segment includes the telemetry center for data communication and the processing center to compute data products and uncertainty budgets. The study shows that the overall uncertainty of EURYBIA SVC gains computed for the Sentinel-3 OLCI mission under EUMETSAT protocols is of about 0.05% in the blue-green wavelengths after a decade of measurements, similar to that of the reference site in Hawaii and in compliance with requirements for climate studies

European radiometry buoy and infrastructure (EURYBIA): A contribution to the design of the European copernicus infrastructure for ocean colour system vicarious calibration

In the context of the Copernicus Program, EUMETSAT prioritizes the creation of an ocean color infrastructure for system vicarious calibration (OC-SVC). This work aims to reply to this need by proposing the European Radiometry Buoy and Infrastructure (EURYBIA). EURYBIA is designed as an autonomous European infrastructure operating within the Marine Optical Network (MarONet) established by University of Miami (Miami, FL, USA) based on the Marine Optical Buoy (MOBY) experience and NASA support. MarONet addresses SVC requirements in different sites, consistently and in a traceable way. The selected EURYBIA installation is close to the Lampedusa Island in the central Mediterranean Sea. This area is widely studied and hosts an Atmospheric and Oceanographic Observatory for long-term climate monitoring. The EURYBIA field segment comprises off-shore and on-shore infrastructures to manage the observation system and perform routine sensors calibrations. The ground segment includes the telemetry center for data communication and the processing center to compute data products and uncertainty budgets. The study shows that the overall uncertainty of EURYBIA SVC gains computed for the Sentinel-3 OLCI mission under EUMETSAT protocols is of about 0.05% in the blue-green wavelengths after a decade of measurements, similar to that of the reference site in Hawaii and in compliance with requirements for climate studies

Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosing interstitial lung diseases (ILDs). We present the design of a multicentre, prospective, double-blind, randomised, placebo-controlled clinical trial of nintedanib in patients with fibrosing chILD (1199-0337 or InPedILD; ClinicalTrials.gov: NCT04093024). Male or female children and adolescents aged 6–17 years (≥30; including ≥20 adolescents aged 12–17 years) with clinically significant fibrosing ILD will be randomised 2:1 to receive oral nintedanib or placebo on top of standard of care for 24 weeks (double-blind), followed by variable-duration nintedanib (open-label). Nintedanib dosing will be based on body weight-dependent allometric scaling, with single-step dose reductions permitted to manage adverse events. Eligible patients will have evidence of fibrosis on high-resolution computed tomography (within 12 months of their first screening visit), FVC ≥25% predicted, and clinically significant disease (Fan score of ≥3 or evidence of clinical progression over time). Patients with underlying chronic liver disease, significant pulmonary arterial hypertension, cardiovascular disease, or increased bleeding risk are ineligible. The primary endpoints are pharmacokinetics and the proportion of patients with treatment-emergent adverse events at week 24. Secondary endpoints include change in FVC% predicted from baseline, Pediatric Quality of Life Questionnaire, oxygen saturation, and 6-min walk distance at weeks 24 and 52. Additional efficacy and safety endpoints will be collected to explore long-term effects